ES2573662T3 - Utilización de mimotopos de epítopos de alfa-sinucleína para el tratamiento de enfermedades de cuerpos de Lewy - Google Patents
Utilización de mimotopos de epítopos de alfa-sinucleína para el tratamiento de enfermedades de cuerpos de Lewy Download PDFInfo
- Publication number
- ES2573662T3 ES2573662T3 ES10747562.6T ES10747562T ES2573662T3 ES 2573662 T3 ES2573662 T3 ES 2573662T3 ES 10747562 T ES10747562 T ES 10747562T ES 2573662 T3 ES2573662 T3 ES 2573662T3
- Authority
- ES
- Spain
- Prior art keywords
- amino acid
- mimotope
- alpha
- acid residue
- alanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000003802 alpha-Synuclein Human genes 0.000 title abstract description 9
- 108090000185 alpha-Synuclein Proteins 0.000 title abstract description 9
- 208000009829 Lewy Body Disease Diseases 0.000 title 1
- 201000002832 Lewy body dementia Diseases 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 11
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
- 150000001413 amino acids Chemical group 0.000 abstract description 5
- 125000000539 amino acid group Chemical group 0.000 abstract 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 5
- 235000004279 alanine Nutrition 0.000 abstract 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004471 Glycine Substances 0.000 abstract 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 2
- 235000009582 asparagine Nutrition 0.000 abstract 2
- 229960001230 asparagine Drugs 0.000 abstract 2
- 235000003704 aspartic acid Nutrition 0.000 abstract 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 2
- 235000013922 glutamic acid Nutrition 0.000 abstract 2
- 239000004220 glutamic acid Substances 0.000 abstract 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 208000032859 Synucleinopathies Diseases 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 238000012216 screening Methods 0.000 description 6
- 102000019355 Synuclein Human genes 0.000 description 2
- 108050006783 Synuclein Proteins 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 102000003799 beta-Synuclein Human genes 0.000 description 1
- 108090000182 beta-Synuclein Proteins 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Composición que comprende por lo menos un péptido o polipéptido que comprende la secuencia de aminoácidos siguiente: (X1)nX2X3X4X5GX6P(X7)m (Fórmula I), en la que: X1 es cualquier residuo aminoácido, X2 es un residuo aminoácido seleccionado de entre el grupo que consiste en lisina (K), arginina (R), alanina (A) e histidina (H), X3 es un residuo aminoácido seleccionado de entre el grupo que consiste en asparagina (N), glutamina (Q), serina (S), glicina (G) y alanina (A), preferentemente asparagina (N), serina (S), glicina (G) y alanina (A), X4 es un residuo aminoácido seleccionado de entre el grupo que consiste en ácido glutámico (E), ácido aspártico (D) y alanina (A), X5 es un residuo aminoácido seleccionado de entre el grupo que consiste en ácido glutámico (E) y ácido aspártico (D), X6 es un residuo aminoácido seleccionado de entre el grupo que consiste en alanina (A) y tirosina (Y), X7 es cualquier residuo aminoácido, n y m, independientemente, son 0 o un número entero superior a 0, y en la que la secuencia de aminoácidos según la fórmula I no es idéntica al, o no comprende el fragmento polipeptídico 7-mero de la alfa-sinucleína que presenta la secuencia de aminoácidos KNEEGAP, presentando dicho por lo menos un péptido o polipéptido una capacidad de unión a un anticuerpo que es específico para un epítopo de alfa-sinucleína que comprende la secuencia de aminoácidos KNEEGAP para la utilización en la prevención y/o el tratamiento de las sinucleinopatías.
Description
sinucleína humana recombinante partiendo del suero 2, respectivamente. En general, se analizaron los sueros mediante la reacción contra péptidos acoplados con albúmina de suero bovino (ASB) y proteínas de longitud completa recombinantes que se inmovilizaron sobre placas de ELIAS. Se determinaron los títulos utilizando anticuerpos específicos anti-IgG de ratón. Para ejemplos de inmunogenicidad contra el péptido inyectado y la alfa
5 sinucleína, ver las Tablas 5 y 6.
2. Resultados
2.1. Identificación de un mAb específico de alfa-sinucleína: la figura 2 ilustra la caracterización del anticuerpo 10 monoclonal específico de la alfa-sinucleína 12-9-9 (IgG1, kappa) derivado de la fusión Affiris 6.
2.2. Cribado para mimotopos específicos de alfa-sinucleína:
2.2.1. Expresión fágica PhD 7, PhD 12 y PhD C7C y cribado mutacional. 15
2.2.1.1. Cribado con anticuerpo monoclonal dirigido contra LGKNEEGAPQ
Mediante el cribado de las bibliotecas de expresión fágica PhD 7, PhD 12 y PhD C7C y el desplazamiento selectivo de aminoácidos individuales, se identificó un total de 60 secuencias (ver la Tabla 1, ID18-77).
20 La Tabla 1 muestra ejemplos de todos los péptidos utilizados.
- SEC ID
- nº de péptido secuencia
- 1
- p4446 Alfa-sinucleína (figura 1; P37840)
- 2
- p4447 Beta-sinucleína; Q16143
- 3
- p4453 LGKNEEGAPQC
- 4
- p4454 MGKGEEGYPQC
- 5
- p5397 GKNEEGAPQC
- 6
- p5398 KNEEGAPQC
- 7
- p5399 NEEGAPQC
- 8
- p5400 EEGAPQC
- 9
- p5401 EGAPQC
- 10
- p5402 LGKNEEGAPC
- 11
- p5403 LGKNEEGAC
- 12
- p5404 LGKNEEGC
- 13
- p5405 LGKNEEC
- 14
- p5406 LGKNEC
- 15
- p5435 CKNEEGAP
- 16
- p5436 KNEEGAPC
- 17
- p1253 DAEFRHDSGY-C
- 18
- p5437 ANEEGAPC
- 19
- p5438 KAEEGAPC
- 20
- p5439 KNAEGAPC
- 21
- p5440 KNEAGAPC
- 22
- p5441 KNEEAAPC
- 23
- p5442 KNEEGAAC
- 24
- p5443 RNEEGAPC
- 25
- p5444 HNEEGAPC
- 26
- p5445 KNDEGAPC
- 27
- p5446 KNEDGAPC
- 28
- p5447 KQEEGAPC
- 29
- p5448 KSEEGAPC
- 30
- p5449 KNDDGAPC
- 31
- p5461 KPSFKNEC
- 32
- p5462 QPSFAMEC
- 33
- p5463 SPSFKQEC
- 34
- p5464 TPSWKGEC
- 35
- p5465 DPSFALEC
- 36
- p5466 LPSFRLEC
- 37
- p5467 EPNSRMDC
- 38
- p5468 QPSSKLDC
- 39
- p5469 HIHQSKFFDAPPC
- 40
- p5547 QASFAMEC
10
- 41
- p5548 TASWKGEC
- 42
- p5549 QASSKLDC
- 43
- p5550 QPAFAMEC
- 44
- p5551 TPAWKGEC
- 45
- p5552 QPASKLDC
- 46
- p5553 QPSFAMAC
- 47
- p5554 TPSWKGAC
- 48
- p5555 QPSSKLAC
- 49
- p5556 APSWKGEC
- 50
- p5557 TPSAKGEC
- 51
- p5558 TPSWAGEC
- 52
- p5559. TPSWKAEC
- 53
- p5560 CTPSWKGE
- 54
- p5587 RNDEGAPC
- 55
- p5588 RNEDGAPC
- 56
- p5589 RQEEGAPC
- 57
- p5590 RSEEGAPC
- 58
- p5591 ANDEGAPC
- 59
- p5592 ANEDGAPC
- 60
- p5593 HSEEGAPC
- 61
- p5594 ASEEGAPC
- 62
- p5595 HNEDGAPC
- 63
- p5596 HNDEGAPC
- 64
- p5597 RNAEGAPC
- 65
- p5598 HNAEGAPC
- 66
- p5599 KSAEGAPC
- 67
- p5600 KSDEGAPC
- 68
- p5601 KSEDGAPC
- 69
- p5602 RQDEGAPC
- 70
- p5603 RQEDGAPC
- 71
- p5604 HSAEGAPC
- 72
- p5605 RSAEGAPC
- 73
- p5606 RSDEGAPC
- 74
- p5607 RSEDGAPC
- 75
- p5608 HSDEGAPC
- 76
- p5609 HSEDGAPC
- 77
- p5610 RQDDGAPC
La Tabla 2 muestra ejemplos de péptidos y de la capacidad de unión de los mismos en comparación con el epítopo original.
- número interno
- secuencia unión observación
- p5435
- CKNEEGAP 2 original
- p5436
- KNEEGAPC 2 original
- p5437
- ANEEGAPC 2 mimotopo
- p5438
- KAEEGAPC 1 mimotopo
- p5439
- KNAEGAPC 2 mimotopo
- p5443
- RNEEGAPC 2 mimotopo
- p5444
- HNEEGAPC 2 mimotopo
- p5445
- KNDEGAPC 2 mimotopo
- p5446
- KNEDGAPC 2 mimotopo
- p5447
- KQEEGAPC 2 mimotopo
- p5448
- KSEEGAPC 2 mimotopo
- p5449
- KNDDGAPC 2 mimotopo
- p5398
- KNEEGAPQC 2 original
- p5402
- LGKNEEGAPC 2 original
- p5397
- GKNEEGAPQC 2 original
- p4454
- MGKGEEGYPQC 2 original
- p4453
- LGKNEEGAPQC 2 original
- p5461
- KPSFKNEC 2 mimotopo
- p5462
- QPSFAMEC 2 mimotopo
- p5463
- SPSFKQEC 2 mimotopo
- p5464
- TPSWKGEC 2 mimotopo
11
- p5465
- DPSFALEC 2 mimotopo
- p5466
- LPSFRLEC 1 mimotopo
- p5468
- QPSSKLDC 2 mimotopo
- p5547
- QASFAMEC 1 mimotopo
- p5548
- TASWKGEC 2 mimotopo
- p5549
- QASSKLDC 1 mimotopo
- p5551
- TPAWKGEC 1 mimotopo
- p5556
- APSWKGEC 2 mimotopo
- p5558
- TPSWAGEC 2 mimotopo
- p5560
- CTPSWKGE 2 mimotopo
- p5587
- --RNDEGAPC 2 mimotopo
- p5588
- --RNEDGAPC 2 mimotopo
- p5589
- --RQEEGAPC 2 mimotopo
- p5590
- --RSEEGAPC 2 mimotopo
- p5591
- --ANDEGAPC 2 mimotopo
- p5593
- --HSEEGAPC 1 mimotopo
- p5594
- --ASEEGAPC 1 mimotopo
- p5596
- --HNDEGAPC 2 mimotopo
- p5597
- --RNAEGAPC 2 mimotopo
- p5598
- --HNAEGAPC 1 mimotopo
- p5599
- --KSAEGAPC 2 mimotopo
- p5600
- --KSDEGAPC 2 mimotopo
- p5601
- --KSEDGAPC 2 mimotopo
- p5602
- --RQDEGAPC 2 mimotopo
- p5603
- --RQEDGAPC 2 mimotopo
- p5604
- --HSAEGAPC 1 mimotopo
- p5605
- --RSAEGAPC 2 mimotopo
- p5606
- --RSDEGAPC 2 mimotopo
- p5607
- --RSEDGAPC 2 mimotopo
- p5608
- --HSDEGAPC 1 mimotopo
- p5610
- --RQDDGAPC 2 mimotopo
- p4446
- 2 α-Syn
Tabla 2: ejemplos de epítopos y mimotopos de alfa-sinucleína ligantes del anticuerpo monoclonal 12-9-9.
La capacidad de unión se codificó según el código siguiente: 5
0: ninguna unión detectable en el ELISA a 12-9-9
1: unión débil: unión del mimotopo más débil que la de la secuencia original mínima p5436
2: unión fuerte: unión del mimotopo similar a la de la secuencia original mínima p5436
10 2.3. Caracterización in vitro de los mimotopos identificados en un cribado (expresión fágica y cribado de péptidos) con un anticuerpo monoclonal dirigido contra la alfa-sinucleína:
Las figuras 2 y 3 muestran ejemplos representativos de los ensayos de unión e inhibición utilizados para caracterizar los mimotopos in vitro. Los datos obtenidos se resumen en las Tablas 2 y 3, respectivamente. 15 Tabla 3: ensayo de inhibición
- denominación
- secuencia competencia observación
- p5435
- CKNEEGAP 1 original
- p5436
- KNEEGAPC 2 original
- p5439
- KNAEGAPC 1 mimotopo
- p5443
- RNEEGAPC 2 mimotopo
- p5445
- KNDEGAPC 2 mimotopo
- p5446
- KNEDGAPC 1 mimotopo
- p5448
- KSEEGAPC 1 mimotopo
- p5449
- KNDDGAPC 1 mimotopo
- p5398
- KNEEGAPQC 2 original
- p5402
- LGKNEEGAPC 2 original
- p5397
- GKNEEGAPQC 2 original
12
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0132409A AT508638B1 (de) | 2009-08-21 | 2009-08-21 | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
| AT13242009 | 2009-08-21 | ||
| PCT/AT2010/000303 WO2011020133A1 (en) | 2009-08-21 | 2010-08-20 | Use of mimotopes of alpha-synuclein epitopes for treating lewy body diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2573662T3 true ES2573662T3 (es) | 2016-06-09 |
Family
ID=42940852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10747562.6T Active ES2573662T3 (es) | 2009-08-21 | 2010-08-20 | Utilización de mimotopos de epítopos de alfa-sinucleína para el tratamiento de enfermedades de cuerpos de Lewy |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8828942B2 (es) |
| EP (1) | EP2467153B1 (es) |
| JP (2) | JP2013502379A (es) |
| KR (2) | KR101517447B1 (es) |
| CN (1) | CN102596224B (es) |
| AT (1) | AT508638B1 (es) |
| AU (1) | AU2010283948B2 (es) |
| BR (1) | BR112012003800A2 (es) |
| CA (1) | CA2771429A1 (es) |
| CY (1) | CY1117582T1 (es) |
| DK (1) | DK2467153T3 (es) |
| ES (1) | ES2573662T3 (es) |
| HK (1) | HK1170658A1 (es) |
| HR (1) | HRP20160594T1 (es) |
| HU (1) | HUE027563T2 (es) |
| IL (1) | IL218207A0 (es) |
| MX (1) | MX2012002153A (es) |
| PL (1) | PL2467153T3 (es) |
| PT (1) | PT2467153E (es) |
| RU (1) | RU2532351C2 (es) |
| SI (1) | SI2467153T1 (es) |
| WO (1) | WO2011020133A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2579042T3 (da) | 2011-10-04 | 2014-07-21 | Affiris Ag | Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve |
| EP2659906A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| EP2659907A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| WO2015075011A1 (en) | 2013-11-21 | 2015-05-28 | F. Hoffmann-La Roche Ag | ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE |
| CA3003943A1 (en) | 2015-11-03 | 2017-05-11 | Affiris Ag | Method for vaccination against a self-antigen in a human patient |
| KR101726549B1 (ko) | 2016-06-29 | 2017-04-12 | 정상문 | 모바일 실시간 시뮬레이션 게임에서의 터치 조작 방식 |
| KR102087494B1 (ko) | 2018-03-15 | 2020-03-10 | 정상문 | 모바일 실시간 시뮬레이션 게임에서 객체를 표시하는 방법 |
| AU2019406749A1 (en) | 2018-12-20 | 2021-05-27 | Saiba AG | Virus-like particles of CMV modified by fusion |
| US20230242601A1 (en) | 2020-07-29 | 2023-08-03 | Tohoku University | Peptide used to prevent or treat synucleinopathy |
| IL300364A (en) | 2020-08-04 | 2023-04-01 | Ac Immune Sa | immunogenic substances |
| BR112023020640A2 (pt) | 2021-04-12 | 2023-12-05 | Saiba AG | Partículas similares a vírus de bacteriófago ap205 modificadas |
| EP4357354A1 (en) * | 2021-06-18 | 2024-04-24 | Sumitomo Pharma Co., Ltd. | Epitope peptide of human alpha-synuclein and pharmaceutical composition including said peptide |
| EP4475878A1 (en) | 2022-02-09 | 2024-12-18 | AC Immune SA | Anti-alpha-synuclein therapeutic vaccines |
| CN119136838A (zh) | 2022-02-28 | 2024-12-13 | 特瑞德姆生物科技有限责任两合公司 | 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物 |
| EP4486388A1 (en) | 2022-02-28 | 2025-01-08 | Tridem Bioscience GmbH & Co KG | A conjugate consisting of or comprising at least a ss-glucan or a mannan |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007325595A (ja) * | 2000-12-22 | 2007-12-20 | Locomogene Inc | 滑膜細胞タンパク質 |
| EP1572894B1 (en) * | 2001-11-21 | 2016-04-13 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto |
| US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) * | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US8697082B2 (en) * | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| JP4820291B2 (ja) | 2003-05-19 | 2011-11-24 | エラン ファーマシューティカルズ，インコーポレイテッド | レヴィー小体病におけるαシヌクレインの切断断片 |
| JPWO2004113535A1 (ja) | 2003-06-22 | 2007-09-20 | 早出 広司 | 凝集抑制作用を有するシヌクレイン変異体 |
| WO2006004066A1 (ja) * | 2004-07-02 | 2006-01-12 | Locomogene, Inc. | S1-5を含有するタンパク質製剤 |
| MX2007001679A (es) * | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| CN101052417A (zh) * | 2004-08-09 | 2007-10-10 | 艾兰制药公司 | 突触核蛋白病以及淀粉样变性病的预防和治疗 |
| ES2407429T3 (es) * | 2005-12-12 | 2013-06-12 | Ac Immune S.A. | Vacuna terapéurica |
| WO2010069603A1 (en) * | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
-
2009
- 2009-08-21 AT AT0132409A patent/AT508638B1/de not_active IP Right Cessation
-
2010
- 2010-08-20 KR KR1020127007123A patent/KR101517447B1/ko not_active Expired - Fee Related
- 2010-08-20 HU HUE10747562A patent/HUE027563T2/en unknown
- 2010-08-20 CN CN201080047744.9A patent/CN102596224B/zh not_active Expired - Fee Related
- 2010-08-20 SI SI201031190A patent/SI2467153T1/sl unknown
- 2010-08-20 MX MX2012002153A patent/MX2012002153A/es active IP Right Grant
- 2010-08-20 US US13/391,552 patent/US8828942B2/en not_active Expired - Fee Related
- 2010-08-20 EP EP10747562.6A patent/EP2467153B1/en active Active
- 2010-08-20 CA CA2771429A patent/CA2771429A1/en not_active Abandoned
- 2010-08-20 JP JP2012524998A patent/JP2013502379A/ja active Pending
- 2010-08-20 ES ES10747562.6T patent/ES2573662T3/es active Active
- 2010-08-20 KR KR1020147028566A patent/KR20140141651A/ko not_active Ceased
- 2010-08-20 AU AU2010283948A patent/AU2010283948B2/en not_active Ceased
- 2010-08-20 RU RU2012110582/15A patent/RU2532351C2/ru not_active IP Right Cessation
- 2010-08-20 DK DK10747562.6T patent/DK2467153T3/en active
- 2010-08-20 BR BR112012003800A patent/BR112012003800A2/pt not_active IP Right Cessation
- 2010-08-20 WO PCT/AT2010/000303 patent/WO2011020133A1/en active Application Filing
- 2010-08-20 PT PT107475626T patent/PT2467153E/pt unknown
- 2010-08-20 PL PL10747562.6T patent/PL2467153T3/pl unknown
-
2012
- 2012-02-20 IL IL218207A patent/IL218207A0/en unknown
- 2012-11-05 HK HK12111092.0A patent/HK1170658A1/zh not_active IP Right Cessation
-
2014
- 2014-09-03 JP JP2014179547A patent/JP5901714B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-01 HR HRP20160594TT patent/HRP20160594T1/hr unknown
- 2016-06-01 CY CY20161100480T patent/CY1117582T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2467153T3 (pl) | 2016-09-30 |
| BR112012003800A2 (pt) | 2016-11-22 |
| EP2467153B1 (en) | 2016-03-02 |
| CA2771429A1 (en) | 2011-02-24 |
| HK1170658A1 (zh) | 2013-03-08 |
| HUE027563T2 (en) | 2016-10-28 |
| MX2012002153A (es) | 2012-03-14 |
| SI2467153T1 (sl) | 2016-07-29 |
| RU2012110582A (ru) | 2013-09-27 |
| US20120156234A1 (en) | 2012-06-21 |
| KR20120059562A (ko) | 2012-06-08 |
| AT508638A1 (de) | 2011-03-15 |
| WO2011020133A1 (en) | 2011-02-24 |
| KR101517447B1 (ko) | 2015-05-28 |
| HRP20160594T1 (hr) | 2016-07-29 |
| PT2467153E (pt) | 2016-06-08 |
| US8828942B2 (en) | 2014-09-09 |
| KR20140141651A (ko) | 2014-12-10 |
| EP2467153A1 (en) | 2012-06-27 |
| CN102596224B (zh) | 2015-12-09 |
| JP5901714B2 (ja) | 2016-04-13 |
| JP2013502379A (ja) | 2013-01-24 |
| JP2015038078A (ja) | 2015-02-26 |
| CY1117582T1 (el) | 2017-04-26 |
| AU2010283948B2 (en) | 2015-01-22 |
| IL218207A0 (en) | 2012-04-30 |
| DK2467153T3 (en) | 2016-06-06 |
| CN102596224A (zh) | 2012-07-18 |
| RU2532351C2 (ru) | 2014-11-10 |
| AU2010283948A1 (en) | 2012-03-29 |
| AT508638B1 (de) | 2011-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2573662T3 (es) | Utilización de mimotopos de epítopos de alfa-sinucleína para el tratamiento de enfermedades de cuerpos de Lewy | |
| ES2550781T3 (es) | Mimotopos de alfa-sinucleína y vacunas de los mismos para el tratamiento de los trastornos neurodegenerativos | |
| ES2296084T3 (es) | Procedimientos para la prevencion y el tratamiento de la enfermedad de alzheimer (ea). | |
| JP5372380B2 (ja) | 結合化合物、免疫原性化合物およびペプチド模倣体 | |
| Timmerman et al. | Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS™ technology | |
| Moudallal et al. | A major part of the polypeptide chain of tobacco mosaic virus protein is antigenic | |
| CN103263664A (zh) | 预防和治疗阿尔茨海默病的方法 | |
| PE20051050A1 (es) | Vacuna para mejorar el crecimiento a base de epitopes neutralizantes | |
| RU98118184A (ru) | Пептидные иммуногены для вакцинации и лечения аллергии | |
| CO6210756A2 (es) | La proteina linfopoyetina estromal timica canina y usos de la misma | |
| ATE225668T1 (de) | Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten | |
| US20070128191A1 (en) | Polyclonal antibodies, preparation method thereof and use of same | |
| Savoca et al. | Epitope mapping employing immobilized synthetic peptides How specific is the reactivity of these peptides with antiserum raised against the parent protein? | |
| ATE349468T1 (de) | Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung | |
| WO2004024770A1 (es) | Anticuerpos policlonales, método de preparación y uso de los mismos | |
| JP2007300856A (ja) | アミロイドタンパク質模倣物 | |
| JP4374316B2 (ja) | β−アミロイドまたはその誘導体に対する抗体およびその用途 | |
| CA3125286A1 (en) | Peptide immunogens targeting interleukin 6 (il-6) and formulations thereof for immunotherapy of diseases impacted by il-6 dysregulation | |
| Ametani et al. | Antibody response of three different strains of mice to αs1-casein analyzed by using proteolytic and synthetic peptides | |
| Nelson et al. | Characterization of anti-myosin monoclonal antibodies | |
| Subramanian et al. | Immunological relatedness of chicken and human riboflavin carrier protein | |
| Alvarenga et al. | Design of antibody-reactive peptides from discontinuous parts of scorpion toxins | |
| CN1441811A (zh) | 能选择性检测朊病毒PrPSc同型异构体的抗体 | |
| NO177858B (no) | Peptid | |
| Lozano et al. | Antibodies induced by Plasmodium falciparum merozoite surface antigen-2-designed pseudopeptides possess neutralizing properties of the in vitro malarial infection |